Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Pharmaceutics · 23.06.2023 · 15 (7) · 1796
DOI: 10.3390/pharmaceutics15071796 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 23.06.2023. Verfasst von Onyinyechi Obidiro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Research and Development, Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC 20059, USA. Die Arbeit wurde bisher 450-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCRR/NIH, NIH/NIGMS.
Abstract (Originalsprache)
Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The survival rate for TNBC is generally worse than other breast cancer subtypes. TNBC treatment has made significant advances, but certain limitations remain. Treatment for TNBC can be challenging since the disease has various molecular subtypes. A variety of treatment options are available, such as chemotherapy, immunotherapy, radiotherapy, and surgery. Chemotherapy is the most common of these options. TNBC is generally treated with systemic chemotherapy using drugs such as anthracyclines and taxanes in neoadjuvant or adjuvant settings. Developing resistance to anticancer drugs and off-target toxicity are the primary hindrances to chemotherapeutic solutions for cancer. It is imperative that researchers, clinicians, and pharmaceutical companies work together to develop effective treatment options for TNBC. Several studies have suggested nanotechnology as a potential solution to the problem of suboptimal TNBC treatment. In this review, we summarized possible treatment options for TNBC, including chemotherapy, immunotherapy, targeted therapy, combination therapy, and nanoparticle-based therapy, and some solutions for the treatment of TNBC in the future. Moreover, we gave general information about TNBC in terms of its characteristics and aggressiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Drug Research and Development, Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC 20059, USA.
ORCID-Profile: Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O Akala
Förderung
- NIGMS NIH HHS
- NCRR/NIH
- NIH/NIGMS
Zitieren
APA
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15(7), 1796. https://doi.org/10.3390/pharmaceutics15071796
Vancouver
Obidiro O, Battogtokh G, Akala EO. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. 2023;15(7):1796. doi:10.3390/pharmaceutics15071796
BibTeX
@article{Obidiro2023,
author = {Obidiro, Onyinyechi and Battogtokh, Gantumur and Akala, Emmanuel O},
title = {Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {7},
pages = {1796},
doi = {10.3390/pharmaceutics15071796}
}
EUVIMED